[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
A Phase II Study of single oral administration of SF-SP containing sustained-release granules of tegafur was conducted in 37 cases of advanced cancers by 9 institutions in the Hokkaido area. Two capsules each containing 200 or 250 mg of SF-SP were orally administered twice daily for a total of either 800 or 1000 mg per day. The results were as follows: Of the 24 evaluable cases PR was observed in 4 cases. (16.7%) The observed efficacy rate by cancer type was 23.5% for gastric cancer and toxicity was observed in 10 (27.8%) of 35 subject cases. These results thus indicate SF-SP to be therapeutically effective for treatment of gastric cancers, with mild toxicity.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003110:Colonic Neoplasms / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004067:Digestive System Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D005641:Tegafur; D005472:Fluorouracil